The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 02, 2024

Filed:

Apr. 05, 2017
Applicant:

Emory University, Atlanta, GA (US);

Inventors:

Edmund Waller, Atlanta, GA (US);

Anna Morris, Atlanta, GA (US);

Christopher Petersen, Atlanta, GA (US);

Jian-Ming Li, Atlanta, GA (US);

Reema Panjwani, Bayside, NY (US);

Jingxia Li, Decatur, GA (US);

Assignee:

Emory University, Atlanta, GA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 5/0783 (2010.01); A61K 45/06 (2006.01); A61K 38/48 (2006.01); A61K 35/17 (2015.01); A61P 35/00 (2006.01); A61K 38/20 (2006.01); A61K 39/39 (2006.01); A61P 31/00 (2006.01); A61K 35/28 (2015.01); A61K 38/22 (2006.01); A61K 38/54 (2006.01); C07K 16/28 (2006.01);
U.S. Cl.
CPC ...
C12N 5/0638 (2013.01); A61K 35/17 (2013.01); A61K 35/28 (2013.01); A61K 38/208 (2013.01); A61K 38/22 (2013.01); A61K 38/482 (2013.01); A61K 38/4886 (2013.01); A61K 38/54 (2013.01); A61K 39/39 (2013.01); A61K 45/06 (2013.01); A61P 31/00 (2018.01); A61P 35/00 (2018.01); C07K 16/28 (2013.01); C12N 5/0636 (2013.01); C12Y 304/21039 (2013.01); C12Y 304/24011 (2013.01); C12N 2501/05 (2013.01); C12N 2501/515 (2013.01);
Abstract

This disclosure relates to compositions and methods of reversing senescence in T cells by interrupting vasoactive intestinal peptide (VIP) signaling and/or inhibiting phosphatidylinositol-3-kinase (PI3 kinase) inhibitor signaling and uses in managing cancer and chronic viral infections. In certain embodiments, the disclosure contemplates methods of reversing T cell senescence by mixing T cell in vitro with an agent that prevents VIP from interacting with VIP receptors and/or a PI3 Kinase inhibitor. In certain embodiments, the disclosure contemplates the expansion of senescent T cells by mixing with a PI3 kinase inhibitor, an agent that block VIP and VIP receptor signaling, a VIP degrading enzyme, and combinations thereof.


Find Patent Forward Citations

Loading…